Symbols

PTCT

Ptc Therapeutics·NASDAQ

--(--)

PTCT fundamentals

PTCT Q4 2025 Earnings

Ptc Therapeutics (PTCT) released its earnings on Feb 19, 2026: revenue was 164.68M (YoY -22.75%), missed estimates; EPS was -1.67 (YoY -96.47%), missed estimates.

Revenue / YoY

164.68M

-22.75%

EPS / YoY

-1.67

-96.47%

Report date

Feb 19, 2026

PTCT Earnings Call Summary for Q4,2025

Sephience Dominates 2026 Outlook: $700M-$800M product revenue target, 19%-36% growth, with U.S. as primary driver and 20+ ex-U.S. launches.
Cash Flow Breakeven Milestone: Potential in 2026 with $1.95B cash, post-Evrysdi royalty sale.
R&D Catalysts: Votoplam Phase III start, vatiquinone open-label study, and MSH3 splicing program advancing to IND.

Earnings

EPS

Revenue

Revenue & Expenses

PTCT has released its 2025 Q4 earnings report, with revenue of 164.68M, reflecting a YoY change of -22.75%, and net profit of -134.97M, showing a YoY change of -104.85%. The Sankey diagram below clearly presents PTCT's revenue sources and cost distribution.

Key Indicators

Ptc Therapeutics (PTCT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ptc Therapeutics (PTCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ptc Therapeutics (PTCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ptc Therapeutics (PTCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown